Experimental stroke drug NCS-01 enters human safety trials
NCT ID NCT03915431
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This early-phase trial tests whether a new drug called NCS-01 is safe for people who have had a stroke. Sixteen patients will receive the drug within 48 hours of their stroke. The main goal is to check for side effects, not to see if the drug works. This is a first step to see if larger studies are possible.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- NCS-01
- What this could lead to
- If safe, this could pave the way for a new treatment to reduce brain damage after a stroke.
- What could go wrong
- This is a very early, small study (16 people) focused only on safety. It is not designed to prove the drug works, and many early-stage treatments fail to show benefit.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ISCHEMIC STROKE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Miami
Miami, Florida, 33136, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Zapping the brain to restore swallowing after stroke?
- Can Brain-Triggered stimulation reawaken arms after stroke?
- Can lifestyle choices after a stroke extend life and prevent a second one?
- Can Clot-Removing devices improve stroke recovery?
- A tiny neck implant could catch Stroke-Causing clots before they reach the brain
- Can virtual games retrain the brain to restore balance?